0      0


JL1102EH - JL1102EH: Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial


Full author listing

Yasmin Karimi, MD,1* Herve Ghesquieres, MD, PhD,2 Wojciech Jurczak, MD, PhD,3 Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc,4 Michael Roost Clausen, MD, PhD,5 Pieternella Lugtenburg, MD, PhD,6 David Cunningham, MD, FRCP, FMedSci,7 Young Rok Do, MD, PhD,8 David John Lewis, MD,9 Robin Gasiorowski, MBBS, FRACP, FRCPA, PhD,10 Tae Min Kim, MD, PhD,11 Marjolein van der Poel, MD, PhD,12 Michelle Limei Poon, MBBS, MRCP,13 Tatyana Feldman, MD,14 Kim M. Linton, MBChB, PhD,15 Anna Sureda, MD, PhD,16 Martin Hutchings, MD, PhD,17 Mariana Cota Stirner, MD, PhD,18 Mariana Sacchi, MD,19 Catherine Thieblemont, MD, PhD20

1University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; 2Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; 3MSC National Research Institute of Oncology, Kraków, Poland; 4Sir Charles Gairdner Hospital, Nedlands, Australia; 5Vejle Hospital, Vejle, Denmark; 6On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; 7The Royal Marsden NHS Foundation Trust, Sutton, UK; 8Keimyung University Dongsan Medical Center, Daegu, Republic of Korea; 9University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK; 10Concord Hospital, University of Sydney, Sydney, Australia; 11Seoul National University Hospital, Seoul, Republic of Korea; 12On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands; 13National University Hospital, Singapore; 14Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ, USA; 15The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; 16Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; 17Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 18AbbVie, North Chicago, IL, USA; 19Genmab, Princeton, NJ, USA; 20Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France

*Corresponding author.